Martin Zizi

Biophysicien PhD

Professeur de physiologie

Ancien Directeur épidémiologiste du Département de la Défense

Ancien Directeur scientifique

Président du Comité d’éthique

EDUCATION

• KATHOLIEKE UNIVERSITEIT TE LEUVEN, Leuven, December 1994,

  • Abilitation/Professorship

  • Thesis Title: “VDAC, a mitochondrial outer membrane channel, physiological regulation and biophysical properties.”

• UNIVERSITY of MARYLAND at COLLEGE PARK (UMCP), 1989-1994.

  • Post-Doctoral. Molecular Biophysics.

• UNIVERSITE LIBRE DE BRUXELLES, Erasmus campus, Brussels, 1988.

  • Preventive medicine for school children degree.

• UNIVERSITE CATHOLIQUE DE LOUVAIN, MD-PhD, Saint-Luc, Brussels, 1980-1987.

  • Medical Doctor Degree, graduated with Summa cum Laude.

• COLLEGE ST. MICHEL, Brussels, 1979-1980.

  • Advanced studies in Higher Mathematics.

• INSTITUT ST. BONIFACE, Brussels,

  • Graduated with Honors (Equivalent to Valedictorian).

 

ACADEMIC POSITIONS

• VRIJE UNIVERSITEIT BRUSSEL. Brussels, November 1999- 2015.

  • Professor of Neurophysiology, Department of Physiology. [Field: Molecular Physics and Neurosciences]

• KATHOLIEKE UNIVERSITEIT TE LEUVEN, Leuven, May 1996-November 1999.

  • Assistant Professor , Department of Physiology, Molecular and Cell Biology. [Field: Molecular Biophysics] 

• KATHOLIEKE UNIVERSITEIT TE LEUVEN, Leuven, March 1994-May 1996.

  • Scientist and Lecturer in the Department of Physiology. [Field: Molecular Biophysics].

• UNIVERSITY of MARYLAND at COLLEGE PARK, College Park, MD, 1992 – Feb 1994.

  • Research Associate in the Department of Zoology, Lab. of Cell Biology. [Field: Biophysics]

• WALTER REED ARMY INSTITUTE OF RESEARCH, Washington D.C., 1990 & 1991.

  • Post-Doctoral fellow in the Department of Nephrology. [Field: Physiology-Medicine]

• KATHOLIEKE UNIVERSITEIT TE LEUVEN, Leuven, 1989.

  • Trainee in A-C noise fluctuations analysis with Dr. W. Van Driessche [Field: Physics].

• UNIVERSITE CATHOLIQUE DE LOUVAIN, Brussels,1987-1989.

  • Teaching and research Assistant to Dr. J. Crabbe, Professor of Renal, Digestive, and Endocrine Physiology. [Field: Physiology-Medicine]

 

GOVERNMENTAL POSITIONS

• JOINT DEFENSE STAFF, BELGIUM, Brussels, 2007- 2014.

  • Direct Advisor to Defense Authorities, back in the laboratory (VUB, and Def) to help create Phage Therapy Clinical Unit.

• JOINT DEFENSE STAFF, BELGIUM, Brussels, 2002- 2007.

  • Chief of the Epidemiology and Biostatistics Division within the Well Being Staff (ACOS WB).

• MEDICAL STAFF OF THE MEDICAL SERVICE, Brussels, Oct 1998-2001.

  • Chief Scientific Officer (MSW), including CBRN, WMD’s.

• MEDICAL STAFF OF THE MEDICAL SERVICE, Brussels, 1996-1997.

  • Scientific Staff Officer within the MSW unit. (MSW is a Scientific and advisory unit of the Belgian Med Corps) CBRN Officer

• ROYAL MILITARY SCHOOL OF THE MEDICAL SERVICE, Gent, 1994-september 1996.

  • NBCE officer (nuclear, biological, chemical and environmental) within the Crisis Medical Management.

• ECOLE ROYALE MILITAIRE, Brussels, 1987-1989.

  • Chief of Medical Detachment.

 

MANAGEMENT/LEADERSHIP ACTIVITIES

• Organization

  • Co-organizer of a Symposium titled “Collaboration Armed Forces-Universities” held in Brussels, april 28, 1995. Keynote Lecture by Nobel Laureate Prof. C. de Duve.
  • 1997-1998. Co-organizer with Prof dr. Verdonck (cardio-physio) of an educational trial program about problem-based education in the Medical Curriculum at KU Leuven. This led to the extension of the program to the main campus.
  • 2000. Creation of a novel unit of Operational Epidemiology in the Dept. of Defense of Belgium
  • Set-up of a novel research group at the VUB (Physiology-Neuro)
  • 2001. Concept and creation of a Biobank with samples from deployed military personnel. This
  • was the first Biobank of this kind in the EU.
  • 2005. Concept and creation of a laboratory of Molecular and Cellular Therapy (Lab MCT) within the Brussels Burn Unit. This lab contains the Brussels Skin Bank, and 2 other biobanks, which were consolidated, fully accredited and ISO-certified.
  • 2009. Creation with colleagues from various EU universities and Defense of the P.H.A.G.E. non- profit, an international group aimed at the evidence-based use of phages (Phage therapy) as a sustainable possible solution to antibiotic resistance.
  • Chairman of the P.H.A.G.E. non profit association from 2009-2013, then vice-chair. Left in 2015.

• Advising

  • 1995-2010. Scientific advisor of the Belgian Delegation at the Biological Weapon Convention (Disarmament talks set in Geneva and in Paris). Between 2001 and 2010, ad hoc advising role for the BE Ministry of Foreign Affairs.
  • Chairperson of the Bioethical Commission of the Belgian Ministry of Defense (MoD). (1997- 2004)
  • Chair of a group (1998-1999) to define and implement the ICD classification encoding in the future BE Army Medical Center.
  • Participant in the Telemedicine Group of the Belgian Forces Medical Corps (1998)
  • Belgian MoD representative to various R&D NATO organizations (RTO, TG, BioMedAC) [Research and Technology Organization, various Task Groups, Biomedical Advisory Committee].
  • Reviewer ad hoc for Pfluegers Arch.- Eur. J. Physiol., Journal of Membrane Biology, BBA, FEBS Letters, Neurophysiology, Environmental Microbiology, grant review for NIH and NATO or the EU DGXII and ERC (EU res council), and NIH (USA).

• Coordination

  • Chair of the BASC (Belgian Anesthesiology Simulator Contact group), June 1999- Dec 2001, Inter-university coordination of the anesthesiology simulator training.

• Science and policy

  • Chief Scientific Officer of BE Med Corps (1997-2001). Policy planning, definitions of priority areas, yearly program and its budgeting and follow-up, Reviews, Tech watch, Inter-departmental coordination and mediation.
  • UNSCOM resident weapon inspector in Baghdad (from Nov 1998- Feb 1999). As the last inspector of the Bio group in 1999, I was one of the main contributor to the design of the new inspection regime known as UNMOVIC, and I helped prevent BE involvement in Irak.
  • Creator and coordinator of an interdisciplinary group tasked by Defense to study the potential long term effects of microwave radar energy within the BE military personnel manning the HAWK and NIKE missile launching systems (Jan 1999-2005).
  • Advices on GSM antenna dosimetry to the appropriate BE Federal authorities.
  • Project Pilot (2000-2002) for redefining BE Military Occupational Medicine in Belgium and Abroad.
  • Creation of an Operational Epidemiology Unit within the Belgian Department of Defense. (2001)
  • Proponent of a novel BE DoD structure: the Veteran Institute.
    
    • Definition, Feasibility and implementation study required to implement a Veteran Institute (IVA) within the Belgian Department of Defense (November 2001)
    • Creation of the Belgian Veteran Administration – Institut des Vétérans (April – October 2002).1
  • Creator of the first BioBank in Belgium
    • Lead to define and implement the Departement of Defense serum and cells repository1 –(Biothèque médicale – Medische biotheek) – (November – December 2001).
    • ii.  Pilot and rapporteur of the implementation phase II of the ‘BE Biothèque’ (June- December 2002).
  • Conceptual development and technical setup of a mobile sampling and detection biological lab deployable for biodefense activities (2002-2003).

• Communication

  • Webmaster of the BE Well Being scientific site (www.smd.be) (1997-2004).
  • Numerous communications both as accredited official or as independent academic to national and international media.
  • Design and contributor to the Federal Gov’t. communication video: ‘Balkan Syndrome: the final diagnosis’.
  • Various papers in mainstream newspapers vulgarizing biology or technology, and their relationships to societal problems
  • Obtained and maintained the confidence of all professional unions during negotiations rounds within Defense to establish and promote Well Being regulations within the Department.
  • Answered numerous questions for parliamentary Commissions/Committees for the Department of Defense (those included Health-care regulations and costs, clinical management, R&D, scientific data, non-conventional weapons and health risks,…).

• Expert missions for the industry.

  • Appointed Independent Expert between two Biotech companies. Protein therapy products.
  • Expert for a major Pharmaceutical group. Protein therapy product. Coaching and advising legal counsels in 3 combined international litigation procedures.
  • Expert under the London Court of Arbitration. Protein therapy products, market size 4 billion/year.
  • Member of the Scientific Council of Eurogentec. Lead to the realization of a strategic study to define and implement the company’s next iteration. (Eurogentec is a 500 person company)
  • Member of the Medical board of Scanadu, Inc. (2011-2014).

• Expert mission for the Courts

  • Expert for the court in 2 cases involving medical complaints against mobile phone operators (2010)
  • Lead of a multidisciplinary independent expert panel appointed by the 1st Instance Tribunal in Tongeren in a case between the Belgacom mobile operator and a mediatized plaintiff.

 

FIELDS OF EXPERTISE/EXPERIENCE

• • Medicine, Electrophysiology, Molecular Biology (applied to cancer research, microbiology).
  • Surface physical chemistry and Biophysics (applied to drug design and protein interactions, and nano- engineering).
  • Teaching at University and at post-graduate levels
  • Science policy planning and
  • Intellectual property in biopharma/biotechnology/mobile phone industry
  • Lived more than 6 years in the
  • Management and leadership
  • Extended experience dealing with the media

 

RECENT PRIVATE SECTOR ACTIVITIES

•  Founder and CSO of AQUANTIS, SA (a Swiss-based startup company aiming for tera-hz spectroscopy-based biosensors).       

  • Stopped participation in 2013, after Company moved to CH.

• CIO (Chief Med and Tech Integration Officer) at SCANADU, Inc. (Mountain View-based company, aiming at mobile health medical technologies).       

  • Left in mid-2014 to start new project… Aerendir.

  • My open-air photometric technology (for urinalysis)

  • just got FDA approval a few weeks ago.

• Founder and CEO of AERENDIR, Inc. (Mountain View, CA) – Company aimed at delivering safe, effective and frictionless authentication products for login and e-commerce.

  • Preparation 2015. Ops started December 2015. 3 B2B products at the gate in June 2018, team of 15 people at the Company.

 

PUBLICATIONS

Mostly in biophysics, in protein structures, molecular technologies, cellular protein trafficking, in environmental bacteriology, virology of phages, and in stats and public health, and cancer metabolism (where patents are also in the pipeline). 5 published papers on COVID (‘21-’23). 1 in review.

• Peer reviewed journals

• • Beauwens, , Beaujean, V., Zizi, M., Rentmeesters, M., Crabbé, J. (1986) Increased chloride permeability of amphibian epithelia treated with aldosterone. Pflugers Archiv 420:620-624.
  • Zizi, M., Fisher, S., Grillo, F.G. (1991) Formation of cation channels in planar lipid bilayers by Brefeldin A. J. Biol. Chem. 266:18443-18445.
  • Zizi, M., Blachly-Dyson, , Forte, M., Colombini, M. (1994) NADH regulates the gating of VDAC, the mitochondrial outer membrane channel. J. Biol. Chem. 269:1614-1616.
  • Lee, A.C., Zizi, M., Colombini, M. (1994) b-NADH decreases the permeability of the mitochondrial outer membrane to ADP by a factor of J. Biol. Chem. 269:30974-30980.
  • Zizi, M., Thomas, , Blachly-Dyson, E., Forte, M., Colombini, M. (1995) Oriented channel insertion reveals the motion of a transmembrane Beta strand during voltage gating of VDAC. Membrane Biol. 144:121-129.
  • Elkeles, , Devos, K.M., Graur, D., Zizi, M., Breiman, A. (1995) Multiple cDNAs of wheat voltage-dependent anion channels (VDAC): isolation, differential expression, mapping and evolution. Plant Mol. Biol. 29:109-124.
  • Lison, Gala, J-L., Zizi, M. (1995) Armée, Universités et Recherche Scientifique: une trilogie à développer. Annales Medicinae Militaris Belgicae 9(2): 75-79.
  • Zizi, M. (1995) On prophylaxis and therapy against chemical NATO Research Study Group 3 report. Annales Medicinae Militaris Belgicae 8(4): 148-149.
  • Elkeles, , Breiman, A., Zizi, M. (1997) Functional differences in yeast-expressed wheat voltage-dependent anion channel isoforms (VDAC). Indication for the presence of a novel modulating protein. J.Biol. Chem. 272:6252-6260.
  • Van Driessche, W., De Smet, P., Li, J., Allen, S., Zizi, M., Mountian, I. (1997) Isovolumetric regulation of cell volume in a distal nephron cell line (A6). J. Physiol. 272:C1890-C1898.
  • Zizi, M., Degrave, (1997) Telemedicine: Technologies, Costs, Applications and Challenges. Annales Medicinae Militaris Belgicae 11(4): 161-163.
  • Bellanger, , Zizi, M. (1997) Medical research priorities in biological arms control and disarmement. (Not available)
  • Zizi, M.  (1997) Of life, glass and water… Why Alice’s mirror is worth more than diamonds. Annales Medicinae Militaris Belgicae 11(1): 7-8.
  • Zizi, M., Byrd, C., Boxus, R., Colombini, M. (1998) VDAC is an ion flow-sensitive. Biophysical J. 75:704-713.
  • Maes,K. , Missiaen, L., Parijs, J.B., Sienaert, I., Bultynckx, G., Zizi, M., De Smet, P., Casteels, (1999) Adenine nucleotide binding site on the inositol 1,4,5-triphosphate receptor bind caffeine but not adenophostin A or cADP-ribose. Cell Calcium 25(2):143-152.
  • Dussein, , Zizi, M. (2000) Le Réseau Neuronal Dynamique Récurrent: Application à l’analyse de mouvements. Annales Medicinae Militaris Belgicae 14(3):117-124.
  • Shi, , Lebrun, P. Umbrain, V., Zizi, M., Camu, F. (2001) Exploring central sensitization with cortical somatosensory evoked potentials in unanaesthetized rats. Eur. J. Anesthesiol. 18:138-139 (suppl).
  • Zizi, M, Heyman, P., Vandenvelde, C. (2002) The assessment of human health risks due to rodent-borne diseases by means of ecological studies of rodent Military Medicine USA 167(1):70-73.
  • Uyttenhove, , Lemmens, M., Zizi, M. (2002) Depleted Uranium in the Balkans: Results of a systematic survey by gamma-spectrometry on soil samples in Kosovo. Health Physics 83(4):543-548.
  • Heyman, P., Klingstrom, J., Dejaghere, F., Leclerc, G., Rozenfeld, F., Escutenaire, S., Vandenvelde, , Zizi, M., Plyusnin, A., Lundkvist, A. (2002) Tula Hantavirus in Belgium. Epidemiology and Infections, 128:251-256
  • Pirnay, JP., De Vos, D., Vanderkelen, A., Cornelis, P., Zizi, M. (2002) Analysis of the Pseudomonas aeruginosa oprD gene from clinical and environmental Environm. Microbiol. 4(12):872-882.
  • Heyman, P., Van Mele, R., De Jaegere, F., Klingström, J., Vandenvelde, C., Lundkvist, A., Rozenfeld, , Zizi, M.. (2002). Distribution of Hantavirus foci in Belgium. Acta Tropica, 84:185-188.
  • Pirnay, , De Vos, D., Cochez C., Bilocq F., Vanderkelen A., Zizi M., Ghysels B., Cornelis P. (2002). Pseudomonas aeruginosa displays an epidemic population structure. Environm. Microbiology (Pseudomonas functional genomics special). 4(12): 898-911.
  • Pirnay, JP., De Vos, D., Cochez C., Bilocq, F., Pirson, J., Struelens, M., Duinslaeger, L., Cornelis, , Zizi, M., Vanderkelen, A. (2003). Molecular epidemiology of Pseudomonas aeruginosa colonization in a burn unit: persistence of a multi-drug resistant and a silver sulphadiazine-resistant clone. J. Clin. Microbiol. 41(3):1192-1202.
  • Heyman, P., Cochez, C., Bigaignon, G., Guillaume, B., Zizi, M., Vandenvelde, C. (2003). Human granulocytic ehrlichiosis in Belgium: an underestimated cause of J. Infect. 47:129-132.
  • Scemes, , Spray, D., Boxus, R., Zizi, M. Lipid bilayer reconstitution of VDAC splice-variants targeted to the cell plasma membrane. Submitted.
  • Shi, , Lebrun, P., Camus, F., Zizi, M. (2003). Intrathecal catheterisation and solvents interfere with cortical somatosensory evoked potential (CSEPs) used in assessing nociception in awake rats. Anesthesiology and Analgesia. 99:159-165.
  • Neirinckx, P., Zizi, M. (2003) Health Risks management during the operational planning process: the Belgian NATO Human Factors and Medicine RTO-MP-109-4:1-9. Also presented at RTO HFM Symposium on “NATO Force Health Protection Requirements from Pre- to Post-Deployment: Population Health for the Military”, Antalya, Turkey, 7-9 April 2003.
  • Pirnay, P., De Vos, D., Zizi, M., Heyman, P. (2003) No easy way to exterminate superbugs at the dawn of ‘the 3rd millenium’. Expert Rev. Anti-infect. Ther. 1(4):89-91.
  • Shi, , Smolders, I., Sarre, S., Michotte, Y., Zizi, M., Camu, F. (2004). Formalin-induced spinal glutamate release in freely moving rats: comparison of two spinal microdialysis approaches. Acta Anest. Belgica 55:43-48.
  • Pirson, , Zizi, M, Jacob, J., Deleuze, J. (2004). Acute ischemic optic neuropathy associated with an abdominal compartment syndrome in a burn patient. Burns 30:491-494.
  • Shi, , Lebrun, P., Camu, F., Zizi, M. (2004) Intrathecal Catheterization and Solvents Interfere with Cortical Somatosensory Evoked Potentials Used in Assessing Nociception in Awake Rats. Anest. Analgesia, 99(3):159-165.
  • Yang, X., Hachimi-Idrissi, S., Zizi, M., Huygens, L. The effects of resuscitative mild hypothermia and oxygen concentration on the survival time during lethal uncontrolled hemorrhagic shock in controlled ventilated Eur. J. Emerg. Med. (accepted, in press).
  • Heyman, A. Plyusnina, Ph. Berny, C. Cochez, M. Artois, M. Zizi, J.P. Pirnay, A. Plyusnin (2004). Seoul hantavirus in Europe: first demonstration of the virus genome from Rattus norvegicus captured in France. Eur. J. Clin. Microbiol. Infect. Dis. 23(9): 711-717.
  • Pirnay, JP;, Cornelis, P., Cochez, C., Zizi, M., Vanderkelen, A., De Vos, D. (2004) Pseudomonas aeruginosa, a versatile, successful and challenging microbe. Adv. In Microbiology, 4:25-41. Book chapter, ed. Mojan R.M. Kerala: Global Research Network.
  • Mullie, , Zizi, M., Degrave, E., Pécheux, C. (2004). Evolutie van de bloedlipiden en van de cardiovasculaire risicofactoren bij een bataljon Belgische soldaten gedurende een verlengde UNO-zending in het Balkangebied (Belbat 13). Tijdschrift voor Geneesk. 60:704-710.
  • Roman, I., Figys, J., Steurs, G., Zizi, M (2005). In vitro interactions between the two mitochondrial membrane proteins, VDAC and cytochrome C Biochemistry, 44:13192- 13201.
  • Degrave, , Autier, P., Grivegnée, A.R., Zizi, M. (2005). All-cause mortality among belgian military radar operators : a 40-year controlled longitudinal study. Eur. J. Epidemiol. 20 :677- 681.
  • Pattyn, N.; Migeotte, P.F.; Kolinsky, R.; Morais, J.; Zizi, M.. (2005). Investigating human cognitive performance during Journal of Gravitational Physiology, 12(1):39-40.
  • Hachimi-Idrissi, , Zizi, M., Nguyen, N., Schiettecate, J., Huygens, L. (2005). The evolution of serum astroglial S-100 b in patients with cardiac arrest treated with mild hypothermia. (2005). Resuscitation 64(2):187-192.
  • Pirnay, JP., Matthijs, S., Colak, H., Chablain, P., Bilocq, F., Van Eldere, J., De Vos, D., Zizi, M., Triest, , Cornelis, P. (2005) Global Pseudomonas aeruginosa biodiversity reflected in a Belgian river. Environm. Microbiology, 7(7):969-981.
  • Figys, J., Vandenbroek, K., Boxus, R., Steurs, G., Roman, I., Zizi, M. (2004) Phage display derived apoptotic modulators acting through the mitochondrial VDAC channel. (Withheld for a patent application.)
  • Roman, , Figys, J., Steurs, G., Zizi, M (2006). Direct measurements of VDAC-actin interactions by surface plasmon resonance. Biochim. Biophys. Acta 1758:479-486.
  • Shi, , Smolders, I., Umbrain, V., Lauwers, MH., Sarre, S., Michotte, Y., Zizi, M., Camu, F. (2006). Peripheral inflammation modifies the effect of intrathecal IL-1b on spinal PGE2 production mainly through cyclooxygenase-2 activity. A spinal microdialysis study in freely moving rats. Pain, 120:307-314.
  • Roman, , Figys, J., Steurs, G., Zizi, M. (2006). Hunting interactomes of a membrane protein : obtaining the largest set of VDAC-interacting protein epitopes. Molecular & Cellular Proteomics 5:1667-1680.
  • Cuignet, , Pirson, J., Soudon, O., Zizi, M. (2007). Effects of gabapentin on morphine consumption and pain in severely burned patients. Burns 33:81-86.
  • Verbeken, , De Vos, D., Vaneechoutte, M., Merabishvili, M., Zizi, M., Pirnay, J.P. (2007). European regulatory conundrum of phage therapy. Future Microbiol. 2:485-491.
  • Merabishvili, , Pirnay, J.P., Verbeken, G., Chanishvili, N., Krylov, V., Mast, J., Van Parijs, L., Lavigne, R., Mattheus, W., Verween, G., De Corte, P., Jennes, S., Zizi, M., De Vos, D., Vaneechoutte, M. (2008). Small-scale production of a bacteriophages cocktail for therapeutic use in accordance with actual legal, ethical and quality assurance standards. PLOS One 4:e4944.
  • Vanhoutte K.J.A., de Asmundis C., Francesconi A., Figys J., Steurs G., Boussy T., Roos M., Mueller , Massimo L., Paparella G., Van Caelenberg K., Chierchia GB, Sarkozy A., Brugada P., Zizi M. (2009) Leaving out control groups: an internal contrast analysis of gene expression profiles in atrial fibrillation patients – A systems biology approach to clinical categorization. Bioinformation 3(6), 275-278.
  • Pirnay, JP., Bilocq, F., Pot, B., Cornelis, P., Zizi, M., Van Eldere, J., De Schaght, P., Vaneechoutte, , Pitt, T., De Vos, D. (2009). Pseudomonas aeruginosa population structure revisited. PLoS ONE. 2009; 4:e7740.
  • Pirnay, JP., Bilocq, F., Pot, B., Cornelis, P., Zizi, M., Van Eldere, J., De Schaght, P., Vaneechoutte, , Pitt, T., Rose, T., Jennes, S., De Vos, D. (2009). Most problematic multidrug resistant Pseudomonas aeruginosa strains in high care and burn units belong to two distinct lineages. Burns. 35:S40.
  • Pirnay, P., De Vos, D., Verbeken, G., Merabishvili, M., Vaneechoutte, M., Zizi, M., Laire, G., Lavigne, R., Huys, I., Van den Mooter, G., Buckling, A., Debarbieux, L., Pouillot, F., Azeredo, J., Kutter, E., Dublanchet, A., Górski, A., Adamia, R. (2011)). The Phage Therapy Paradigm: « Prêt à Porter » or « Sur-mesure » ? Pharmaceutical Res 28(4):934-937.
  • Pirnay, P., Vanderkelen, A., De Vos, D., Zizi, M., Ectors, N., Verbeken, G. Human Cells and Tissues: Need for a Global Ethical Framework. (2010) Bulletin of the World Health Organ. 88(11):870-872.
  • Pirnay, P., Verbeken, G., Rose, T., Jennes, S., Zizi, M., Huys, I., Lavigne, R., Vaneechoutee, M., Buckling, A. De Vos, D. (2012) Introducing yesterday’s phage therapy in tomorrow’s medicine. Future Virology 7(4):379-390.
  • Verbeken, , Pirnay, J.P., De Vos, D., Jennes, S;, Zizi, M., Lavigne, R., Casteels, M., Huys, I. (2012). Optimizing the European regulatory frame for sustainable bacteriophage therapy in human medicine. Arch. Immunol. Ther. Experiment. 3(60):161-172. (DOI 10.1007/s00005- 012-0175-0)
  • Pirnay, JP., Vanderkelen, A., Ectors N., Delloye, C., Dufrane, D., Baudoux, E., Van Brussel, M., Casaer, M., De Vos, D., Draye, JP., Rose, T., Jennes, S., Neirinckx, P., Laire, G., Zizi, M., Verbeken, (2012) Beware of the commercialization of human cells and tissues: situation in the European Union. Cell and Tissue Banking. 13(3):487-498.
  • Matvejev, , Zizi, M., Stiens J. (2012) Hydration shell parameters of aqueous alcohols : TeraHerz absorption and packing density. J. Phys. Chem B 116(48) :14071-14077.
  • Rose, T., Verbeken, G., De Vos, D., Merabishvili, M.,Vaneechoutte, M., Lavigne, R., Jennes, S., Zizi, , Pirnay, JP. (2014). Experimental phage therapy of burn wound infection: difficult first steps. Int J Burn Trauma 4(2):66-73.
  • Pirnay, JP, Blasdel, B, Bretaudeau, L, Buckling, A, Chanishvili, N, Clark, JR, Corte-Real, S, Debarbieux, L, Dublanchet, A, De Vos, D, Gabard, J, Garcia, M, Goderdzishvili, M, Górski, A, Hardcastle, Huys, H, Kutter, E, Lavigne, R, Merabishvili, M, Olchawa, E, Parikka, KJ, Patey, O, Pouilot, F, Resch, G, Rohde, C, Scheres, J, Skurnik, M, Vaneechoutte, M, Van Parys, L, Verbeken, H, Zizi, M, Van den Eede, G. (2014) Quality and safety requirements for sustainable phage therapy products. Pharm. Res. DO I10.1007/s11095-014-1617-7
  • Figys, , Steurs, G., Zizi, M. (2016). VDAC as the extrinsic controller of the mitochondrially- encoded protein subunits of the electron transport chain. Accepted for publication in Mol. Cellular Proteomics.
  • Paul, , Brown, G., Deschanp, M., Kalk, A., Laterre, PF.,Rentier, B., Ridde, V., Zizi, M. (2021). COVID-19: an extra-terrestrial disease? Int. J. of Infect. Diseases. 110:155-159 https://doi.org/10.1016/j.ijid.2021.07.051
  • Durnell, , Okabe-Miyamoto, K., Howell, R., Zizi, M. (2020). Online privacy breaches, offline consequences: construction and validation of the concerns with the protection of informational privacy scale. Int. Journal of Human–Computer Interaction. 36(19):1834-1848.
  • Durnell, E., Okabe-Miyamoto, K., Howell, R., Zizi, M. (2021). Did zoom bomb? Negative video conferencing meetings during COVID‐19 undermined worker subjective Hum Behav & Emerg Tech. 3:1067–1083. DOI: 10.1002/hbe2.317
  • Okabe-Miyamoto, K., Durnell, E., Howell, R., Zizi, M. (2022). Video conferencing during emergency distance learning impacted student emotions during COVID-19 Computers Human Behavior Reports, 7:100-199. https://doi.org/10.1016/j.chbr.2022.100199
  • Kalk, A., Sturmberg, J., Van Damme, W., Brown, G., Ridde, V., Zizi, M. Paul. E. (2022). Surfing the corona waves instead of breaking them – Rethinking the role of natural immunity in COVID-19 policy. F1000 Research Masr 2022. https://doi.org/10.12688/f1000research.110593.1
  • Lucier, D., Howell, R.T., Okabe-Miyamoto, K., Durnell, E., Zizi, M. (2023) We make a nice pair: Pairing the mID with a NeuroTechnology privacy enhancing technology improves mID download intentions. Computers in Human Behavior Reports DOI: https://doi.org/10.1016/j.chbr.2023.100321

PATENTS (not complete list)

• • EP20040447298. with priority data 23/12 2004. Method for screening and selecting ligands. Publication number EP1674568. Granted.
  • Divisional based on former. Granted
  • Inventor WO 2006/066368, publication date 29/06/2006.
  • Co-Inventor. Methods of Data Acquisition Quality and Data Fusion for Personal Portable Wireless Vital Signs Scanner. US Provisional. 61/924,230. US Non Prov. 14/292,820
  • Co-Inventor. Self-Calibrating non-invasive cuffless Blood Pressure Measurement Method and Device. US Provisional 61/949,235.
  • Co-Inventor. Method & apparatus for performing & quantifying color changes induced by specific concentrations of biological analytes w/ high accuracy in a self-calibrating US Provisional. 61/680,842. PCT Filing PCT/US2013/035397
  • Co-Inventor. Apparatus for Determining Analyte Concentration by Quantifying and Interpreting Color Information captured in a continuous or periodic manner. US Provisional. 61/948,536
  • Co-Inventor. Generic Apparatus and Method Enhancing Color Vision and Quantifying Color Interpretation on Head-mounted-display. US Provisional. 61/973,208
  • Signal Embedded Signatures. US Provisional. 61/937,437.
  • Co-Inventor. Local User Identification with Neuromechanical US Provisional 62/112153.
  • Co-Inventor. Sequamers – A novel non-natural type of peptide libraries randomly constrained by their primary sequences. US Provisional 61/947,292 PCT Filing PCT/EP2015/054397.
  • Holder of 32 patents in neurotechnology relative to encryption, authentication, access control of IoT connected devices , and health/wellness variations. All IP were filed and granted between 2017 and 2023, 25 more are pending